Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Sunesis Pharmaceuticals Initiates Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS


Sunesis Pharmaceuticals (Nasdaq: SNSS) today announced the initiation of an investigator-sponsored trial of vosaroxin in combination with azacitidine in patients with myelodysplastic syndrome (MDS). The trial is being conducted at the Washington University School of Medicine under the direction of Meagan A. Jacoby, M.D., Ph.D., Instructor of Medicine, Division of Oncology.

"Additional therapeutic options are needed for patients with MDS," said Dr. Jacoby. "While azacitidine has been shown to improve survival in patients with high-risk MDS, existing therapies do not produce a remission in the majority of patients and are not curative. Given its clinical profile, we believe that investigation of vosaroxin's activity in high-risk MDS is warranted."

The Phase 1/2, open label, dose-escalation trial will enroll up to approximately 40 patients with MDS who may have received up to three prior cycles of hypomethylating agent-based therapy. Patients will receive vosaroxin (days one and four) and azacitidine (days one through seven) for a maximum of six cycles. This dose escalation study is designed to enroll six patients per cohort in order to determine the maximum tolerated dose (MTD) and dose limiting toxicity of the combination. Other endpoints include best response, safety, tolerability,

See full press release

Posted-In: News Guidance Management Global


Related Articles (SNSS)

View Comments and Join the Discussion!

Kratos' SecureInfo Awarded $1.5M Task Order to Support US Air Force Cybersecurity Operations

US Stock Futures Up Ahead Of Wholesale Trade Data